HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J on consumer biz

This article was originally published in The Rose Sheet

Executive Summary

Emerging markets, including China, Brazil, Russia and India, offer "fertile ground for the consumer business to grow" and will likely lead the business segment on the road to recovery, Johnson & Johnson says during March 2 RBC Capital Markets Healthcare Conference in which it discussed its business relative to the recession. Marketer of Neutrogena, Clean & Clear and Aveeno skin-care lines already has made selective acquisitions in developing markets to "gain a foothold into certain tiers" of the consumer segment where it did not formerly compete. The most significant of those acquisitions was Dabao skin care in China (1"The Rose Sheet" Aug. 4, 2008, In Brief). J&J's international skin-care sales grew 14.2% on a reported basis in its fourth quarter, as announced in late January (2"The Rose Sheet" Feb. 1, 2010)

Latest Headlines
See All
UsernamePublicRestriction

Register

RS016776

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel